Trial Outcomes & Findings for Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor (NCT NCT03656172)

Results Overview

Spearman correlation between RET-He measured at baseline (initial blood test) and hemoglobin level measured 1 month after intravenous iron treatment.

Recruitment status

COMPLETED

Target enrollment

51 participants

Primary outcome timeframe

1 month after inclusion

Results posted on

2026-08-17

Participant Flow

Participant milestones

Participant milestones
Measure	Haemoglobin Measure Haemoglobin measure: Haemoglobin measure before and one month after standard iron treatment
Overall Study STARTED	51
Overall Study COMPLETED	51
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Haemoglobin Measure n=51 Participants Haemoglobin measure: Haemoglobin measure before and one month after standard iron treatment
Age, Continuous	66.2 years n=51 Participants
Sex: Female, Male Female	37 Participants n=51 Participants
Sex: Female, Male Male	14 Participants n=51 Participants
Region of Enrollment France	51 participants n=51 Participants

PRIMARY outcome

Timeframe: 1 month after inclusion

Population: Analysis included participants with available RET-He measurement at baseline and hemoglobin measurement at 1 month after intravenous iron treatment (n=51).

Spearman correlation between RET-He measured at baseline (initial blood test) and hemoglobin level measured 1 month after intravenous iron treatment.

Outcome measures

Outcome measures
Measure	Participants With Available RET-He and Hemoglobin Measurements n=51 Participants Participants with baseline RET-He measurement and hemoglobin assessment 1 month after intravenous iron treatment.
Spearman Correlation Coefficient Between RET-He at Baseline and Hemoglobin at 1 Month After Intravenous Iron Treatment	-0.278 Spearman correlation coefficient

SECONDARY outcome

Timeframe: 1 month

Percentage of participants achieving a hemoglobin increase of ≥1 g/dL from baseline to 1 month after intravenous iron treatment, with or without erythropoiesis-stimulating agent.

Outcome measures

Outcome measures
Measure	Participants With Available RET-He and Hemoglobin Measurements n=51 Participants Participants with baseline RET-He measurement and hemoglobin assessment 1 month after intravenous iron treatment.
Percentage of Participants With Hemoglobin Increase ≥1 g/dL 1 Month After Intravenous Iron Treatment (With or Without Erythropoiesis-stimulating Agent)	64.7 Percentage of participants

Adverse Events

Haemoglobin Measure

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Mathilde DUPE

Institut de Cancérologie de l'Ouest

Phone: +33 2 40 67 99 00

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place